Clinical Trials
8 trialsNCT00128102 2020-10-26
MK-0683-014
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT00667082 2017-11-22
NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma
Celgene
Phase 1 Completed
NCT00126451 2017-04-10
A Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Relapsed or Refractory Breast, Colorectal and Non-Small Cell Lung Cancer (0683-011)(TERMINATED)
Merck Sharp & Dohme LLC
Phase 2 Terminated
NCT00423449 2016-02-04
Clinical Trial of MK0683 in Combination With FDA Approved Cancer Drugs in Patients With Advanced NSCLC (MK0683-058)
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT00473889 2015-07-03
A Clinical Trial of Vorinostat (MK0683, SAHA) in Combination With FDA Approved Cancer Drugs in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)(0683-056)
Merck Sharp & Dohme LLC
Phase 2/3 Terminated
NCT00424775 2015-04-20
A Study of Carboplatin + Paclitaxel and MK0683 in Patients With Chemotherapy-naive Non-Small Cell Lung Cancer (NSCLC)(0683-066)
Merck Sharp & Dohme LLC
Phase 1 Terminated
NCT00251589 2015-03-06
A Phase I/II Clinical Trial of Vorinostat in Combination With Erlotinib for Patients With Relapsed/Refractory Non-Small-Cell Lung Cancer (0683-025)
Merck Sharp & Dohme LLC
Phase 1/2 Terminated
NCT00106626 2009-04-22
Suberoylanilide Hydroxamic Acid in Advanced Solid Tumors
Merck Sharp & Dohme LLC
Phase 1 Completed